The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.
Let’s assume you are not an expert highly trained in medical imaging. And let’s assume you were invited one day to try out a new technology for heart ultrasounds — diagnostic tools that are notoriously difficult to use because of the chest wall and because some shots must be made while the heart is in motion.
Precisa ter o programa Access instalado
Dê sua opinião sobre o novo desenho de página.
AMVT- Accessory mitral valve tissue – is a rare congenital cardiac anomaly usually diagnosed during childhood and rarely reported in the adult population. To our knowledge this complex congenital mitral valve pathology involving AMVT of the lateral mitral commissure combined with an associated anomalous left atrial chordae has hitherto gone unreported. Echocardiography plays an important role in diagnosing this condition, with TEE often providing more information than TTE. AMVT remains a complex congenital cardiac anomaly, and this case highlights a previously unreported manifestation.
Outras causas de refluxo Mitral que precisamos procurar.